Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Cerus Corp (NASDAQ:CERS)

4.39
Delayed Data
As of Jan 20
 +0.08 / +1.86%
Today’s Change
4.07
Today|||52-Week Range
7.64
+0.92%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Medical Specialties
MARKET CAP
$454.2M

Company Description

Cerus Corp. is a biomedical products company, which is engaged in developing and commercializing the INTERCEPT blood system. The INTERCEPT blood system is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. It markets and sells the INTERCEPT blood system for both platelets and plasma in Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.

Contact Information

Cerus Corp.
2550 Stanwell Drive
Concord California 94520
P:(925) 288-6000
Investor Relations:
(925) 288-6319

Employees

Shareholders

Individual stakeholders4.76%
Other institutional35.89%
Mutual fund holders34.56%

Top Executives

William Mariner GreenmanPresident, Chief Executive Officer & Director
Suzanne MargerumVice President-Manufacturing & Operations
Kevin Dennis GreenChief Financial Officer & Vice President
Laurence M. CorashDirector, Chief Scientific Officer & Senior VP
Adonis StassinopoulosVP-Global Scientific Affairs & Research